KRROHIGH SIGNALRISK10-K

KRRO experienced clinical trial setbacks with its lead AATD program and implemented significant organizational restructuring amid deteriorating financial performance.

The language changes reveal that KRRO's Phase 1/2a REWRITE clinical trial for KRRO-110 failed to meet expectations, forcing the company to pivot from actively dosing participants to acknowledging negative results. The addition of workforce reduction commentary and paused Novo Nordisk collaboration indicates the company is in crisis management mode, struggling to maintain operations while seeking new strategic direction.

Comparing 2026-03-12 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

KRRO's financial position deteriorated markedly, with cash reserves declining substantially from $55.6M to $21.8M and stockholders' equity falling dramatically to $51.4M. Operating losses widened meaningfully while the company sharply reduced capital expenditures from $17.9M to just $518K, signaling aggressive cost-cutting measures. The overall financial picture suggests a biotech company burning through cash rapidly while scaling back investments following clinical disappointments.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-97.1%
$17.9M→$518K

Capex reduced 97.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
-67.9%
$160.4M→$51.4M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
-60.8%
$55.6M→$21.8M

Cash declined 60.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Assets
Balance Sheet
-49.8%
$226.2M→$113.5M

Total assets contracted 49.8% — asset sales, write-downs, or balance sheet optimization underway.

Net Income
P&L
-40.3%
-$83.6M→-$117.3M

Net income declined 40.3% — review whether driven by operations, interest costs, or non-recurring items.

Current Assets
Balance Sheet
-37.4%
$131.5M→$82.4M

Current assets declined 37.4% — monitor working capital adequacy and short-term liquidity.

Operating Income
P&L
-32.6%
-$91.9M→-$121.9M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Operating Cash Flow
Cash Flow
-30.8%
-$60.1M→-$78.6M

Operating cash flow fell 30.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Interest Expense
P&L
+25.8%
$764K→$961K

Interest costs rose 25.8% — monitor debt levels and coverage ratio in rising rate environment.

Current Liabilities
Balance Sheet
-20.2%
$15.0M→$11.9M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-18
ADDED
In this Annual Report, when we refer to our leads or lead candidates, we are referring to our oligonucleotides that we are researching for potential nomination as a development candidate.
When we refer to our development candidates, we generally mean an oligonucleotide lead candidate that we have nominated for clinical development.
If preclinical studies or clinical trials of any lead candidates or development candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results (such as we experienced in the Phase 1/2a REWRITE clinical trial of KRRO-110 for AATD), we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such development candidates.
We may not realize the anticipated benefits of our organizational streamlining and workforce reduction..
We have yet to successfully complete clinical development of any development candidate, and any favorable results we have may not be predictive of results that may be observed in later preclinical studies or clinical trials, such as our experience in the Phase 1/2a REWRITE clinical trial of KRRO-110 for AATD.
+7 more — sign up free →
REMOVED
We have dosed very few participants in our Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency, or AATD, and not received any clinical trial results for any of our proposed delivery methods or RNA editing approaches in clinical trials.
Any favorable results we may have may not be predictive of results that may be observed in later preclinical studies or clinical trials.
If preclinical studies or clinical trials of any product candidates we may identify and develop fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates.
If we experience delays or difficulties in the enrollment of patients in clinical trials, or other delays in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
Our business may be impacted by macroeconomic conditions, including fears concerning the financial services industry, inflation, rising interest rates and volatile market conditions, and other uncertainties beyond our control.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →